ENTITY
Shenzhen Hepalink Pharmaceutical

Shenzhen Hepalink Pharmaceutical (9989 HK)

97
Analysis
Health Care • China
Shenzhen Hepalink Pharmaceutical is a multinational biopharmaceutical company with core businesses in the heparin industrial chain, large molecule biologics CDMO services, and the research, development, and commercialization of innovative drugs. Its key products include heparin sodium APIs and enoxaparin sodium preparations. The company is headquartered in Shenzhen, China, and was founded in 1998.
more
•12 Dec 2022 08:05

A-H Premium Weekly (Dec 9th): Weichai Power, Shanghai Fudan, Guolian, Joinn Lab, GWC, Tsingtao

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Weichai Power, Shanghai Fudan, Guolian Securities, Joinn...

Logo
477 Views
Share
•06 Nov 2022 14:03

A-H Premium Weekly (Nov 4th): First Tractor, Maanshan Iron

We analyzed A-H premium changes in the past week and highlight A-H premium changes for First Tractor, Maanshan Iron, Datang Intl, Cansino, Jushi,...

Logo
304 Views
Share
•26 Jun 2022 11:20

A-H Premium Weekly: Zhejiang Shibao, PICC, CRRC

We highlight week-on-week A-H premium changes in stocks including Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.

Logo
412 Views
Share
•05 Jun 2022 11:53

A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

We highlight A-H premium changes for stocks including Remegen, CNOOC, COSCO Shipping, Cansino, Nanjing Panda, Shenzhen Hepalink, SH Fudan, SH...

Logo
502 Views
Share
•10 Apr 2022 12:01

A-H Premium Weekly: Healthcare Led Premium Decline

A-H premium declined by 3.0ppt last week, led by consumer staple, consumer discretionary and heathcare. We highlight names including Shenzhen...

Logo
473 Views
Share
x